Stock listing

Frankfurt:4TZ Oric Pharmaceuticals, Inc. Aktie

German listing (Frankfurt) of Oric Pharmaceuticals, Inc. · home listing NASDAQ:ORIC

Follow Oric Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · FWB:4TZ

€10.83 EUR +0.64 (+6.3%)

Close on Oct 16, 2026

Day range
€10.83 – €11.18 EUROct 16, 2026
Market value
€1.12B EURAt the close on Oct 16, 2026 · price × 103.7M shares outstanding
Oric Pharmaceuticals, Inc. logo
Ticker
Frankfurt:4TZ
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Replays

  • Oric Pharmaceuticals (NASDAQ:ORIC) Q4 2021 Earnings Call

    Mon, Mar 21, 2022 · 5:00 PM ET

    Watch Transcript

Latest news

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

Oct 19, 2026

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

Oct 5, 2026

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 2, 2026

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

Aug 3, 2026

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

Jul 20, 2026

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

Jul 14, 2026

ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

May 4, 2026

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Apr 17, 2026

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

Mar 31, 2026

ORIC Pharmaceuticals to Report Combination Dose Optimization Data from Phase 1b Trial of Rinzimetostat in Patients with mCRPC

Mar 30, 2026

All Oric Pharmaceuticals, Inc. news

Decks

Oric Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
27 in the last 12 months · 132 in all · newest Oct 19, 2026 · oldest 2020
Calls
1 call with a replay · 1 with a transcript · latest Mar 21, 2022
Decks
10 decks · latest September 2026

Where Oric Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ORIC · Home listingNASDAQUnited StatesUSD
LS Exchange:A2P208LS ExchangeGermanyEUR
Lang & Schwarz:A2P208Lang & SchwarzGermanyEUR
gettex:4TZgettexGermanyEUR
BOATS:ORICBOATSUnited StatesUSD
Tradegate:4TZTradegateGermanyEUR
Dusseldorf:4TZDusseldorfGermanyEUR
Frankfurt:4TZ · This pageFrankfurtGermanyEUR
Hamburg:4TZHamburgGermanyEUR
Munich:4TZMunichGermanyEUR
Stuttgart:4TZStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Oric Pharmaceuticals, Inc.